Amgen Inc. (AMGN) analyst actions
Rating and price-target actions on AMGN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AMGN overview →
1 measured AMGN analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY | Press release | -2.25% | +5.47% |
Keep exploring
More AMGN: earnings → · SEC filings → · AMGN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INTELLIPHARMACEUTICS (IPCI) | 619 | -0.40% | 39% |
| Neurocrine Biosciences, Inc. (NBIX) | 619 | -0.14% | 42% |
| Jounce Therapeutics, Inc. (JNCE) | 612 | 0.00% | 48% |
| Bausch Health Companies Inc. (BHC) | 610 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.